Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in First-line KIT/PDGFR Wild Type GIST
NCT02638766Phase 2Completed
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Nov 2015
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in gastrointestinal stromal tumor (GIST), sponsored by Spanish Group for Research on Sarcoma. Primary endpoint: Disease Control Rate. Started Nov 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02638766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638766.